
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
GRI Bio Inc. (GRI)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GRI (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $22
1 Year Target Price $22
1 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.74% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.50M USD | Price to earnings Ratio 0.02 | 1Y Target Price 22 |
Price to earnings Ratio 0.02 | 1Y Target Price 22 | ||
Volume (30-day avg) 2 | Beta -1.83 | 52 Weeks Range 1.10 - 30.43 | Updated Date 08/29/2025 |
52 Weeks Range 1.10 - 30.43 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 90.8 |
Earnings Date
Report Date 2025-08-14 | When Before Market | Estimate -1.31 | Actual -1.31 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -98.68% | Return on Equity (TTM) -248.92% |
Valuation
Trailing PE 0.02 | Forward PE - | Enterprise Value -1529727 | Price to Sales(TTM) - |
Enterprise Value -1529727 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 2515300 | Shares Floating 2514701 |
Shares Outstanding 2515300 | Shares Floating 2514701 | ||
Percent Insiders 0.02 | Percent Institutions 0.78 |
Upturn AI SWOT
GRI Bio Inc.
Company Overview
History and Background
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory, fibrotic, and autoimmune diseases. Founded in 2020, GRI Bio is leveraging its Tissue-Targeted Therapeuticsu2122 (TTT) platform to discover and develop targeted therapies that can selectively modulate the immune system at the site of disease. GRI Bio merged with Vallon Pharmaceuticals, Inc. in 2023.
Core Business Areas
- GVIN Module Program: Lead program targeting innate immune checkpoint VISTA (V-domain Ig suppressor of T cell activation) for treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.
- Platform Technology: Tissue-Targeted Therapeuticsu2122 (TTT) platform to discover and develop targeted therapies that can selectively modulate the immune system at the site of disease.
Leadership and Structure
The leadership team includes CEO Dr. Bedi, as well as other executives with expertise in drug development and commercialization. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- GVIN Module: Lead program targeting VISTA. Currently in clinical development for IPF. Market share is not yet applicable as the product is pre-revenue. Competitors in IPF include Boehringer Ingelheim (OFEV and Vargatramestan) and Roche (Esbriet).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with significant investment in research and development. The market for inflammatory and fibrotic disease therapies is substantial and growing.
Positioning
GRI Bio is positioned as a company with a novel approach to treating inflammatory and fibrotic diseases, utilizing its TTT platform to develop targeted therapies. Its competitive advantage lies in its potential to develop more effective and safer treatments compared to existing therapies.
Total Addressable Market (TAM)
The TAM for IPF alone is estimated to be multi-billion dollar and could be a good indication. GRI Bio targets larger fibrosis markets. The company focuses on innovative treatment of the disease
Upturn SWOT Analysis
Strengths
- Novel TTT platform
- Targeting VISTA, a promising immune checkpoint
- Experienced management team
- Strong IP portfolio (pending & granted)
Weaknesses
- Early stage clinical development
- Limited financial resources
- Reliance on successful clinical trial outcomes
- Dependency on key personal
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into other inflammatory and fibrotic diseases
- Positive clinical trial results leading to regulatory approval
- Further development of TTT platform
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BI
- Roche
- Bristol Myers Squibb (BMY)
Competitive Landscape
GRI Bio competes with established pharmaceutical companies that have approved therapies for inflammatory and fibrotic diseases. GRI Bio's competitive advantage lies in its novel TTT platform and its focus on VISTA, but it faces challenges related to its early stage of development and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is relatively new. Growth is primarily focused on advancing its clinical programs.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst estimates are not available at this time.
Recent Initiatives: Advancing the GVIN module into further clinical trials; expanding preclinical research efforts; searching for partnership opportunities to enhance the TTT platform and program advancement.
Summary
GRI Bio is an early-stage biopharmaceutical company with a promising platform technology for treating inflammatory and fibrotic diseases. Its focus on VISTA and targeted therapies could lead to significant breakthroughs. The company's success depends on successful clinical trials and securing partnerships to advance its programs. It needs to monitor risks to the trials and look for partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- GRI Bio Inc. corporate website
- SEC Filings
- Industry Reports
- Analyst Reports (where available)
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimated and may not be precise. Financial data may be outdated. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GRI Bio Inc.
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2021-02-10 | Co-Founder, CEO, President & Director Dr. W. Marc Hertz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.gribio.com |
Full time employees 3 | Website https://www.gribio.com |
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.